Merus N.V. (MRUS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Sven Ante Lundberg M.D. | CEO, President & Executive Director | 1.11M | -- | 1963 |
| Mr. Gregory D. Perry | Chief Financial Officer | 419.1k | -- | 1960 |
| Mr. Peter B. Silverman J.D. | EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal | 781.84k | 565.02k | 1978 |
| Dr. Andrew Joe M.D. | Consultant | 685.12k | -- | 1966 |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor | -- | -- | -- |
| Harry Shuman | Chief Accounting Officer | -- | -- | -- |
| Mr. Cornelis Adriaan de Kruif Ph.D. | CTO & Executive VP | 362.04k | -- | 1965 |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer & Senior VP | -- | -- | -- |
| Kathleen Farren | IR & Corporate Communications Officer | -- | -- | -- |
| Mr. Alexander Berthold Hendrik Bakker Ph.D. | Executive VP, Chief Development Officer & Head of Merus Utrecht | 410.08k | -- | 1966 |
Merus N.V.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 172
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Corporate Governance
Upcoming Events
October 31, 2024 at 10:59 AM UTC - November 4, 2024 at 12:00 PM UTC
Merus N.V. Earnings Date